FR2845594A1 - Cosmetic or dermatological composition useful for care and treatment of the skin comprises Spanish juniper oil and rosemary, sandalwood and/or helichrysum oil - Google Patents
Cosmetic or dermatological composition useful for care and treatment of the skin comprises Spanish juniper oil and rosemary, sandalwood and/or helichrysum oil Download PDFInfo
- Publication number
- FR2845594A1 FR2845594A1 FR0212543A FR0212543A FR2845594A1 FR 2845594 A1 FR2845594 A1 FR 2845594A1 FR 0212543 A FR0212543 A FR 0212543A FR 0212543 A FR0212543 A FR 0212543A FR 2845594 A1 FR2845594 A1 FR 2845594A1
- Authority
- FR
- France
- Prior art keywords
- composition
- oil
- rosemary
- composition according
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 235000008632 Santalum album Nutrition 0.000 title claims abstract description 16
- 239000002537 cosmetic Substances 0.000 title claims abstract description 16
- 244000178231 Rosmarinus officinalis Species 0.000 title claims abstract description 12
- 239000003921 oil Substances 0.000 title abstract description 10
- 241000766749 Juniperus thurifera Species 0.000 title abstract 2
- 240000000513 Santalum album Species 0.000 title abstract 2
- 239000010653 helichrysum oil Substances 0.000 title abstract 2
- 239000010668 rosemary oil Substances 0.000 title abstract 2
- 239000010671 sandalwood oil Substances 0.000 title abstract 2
- 239000000341 volatile oil Substances 0.000 claims description 50
- 241000221035 Santalaceae Species 0.000 claims description 14
- 244000308760 Helichrysum petiolatum Species 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 8
- 230000003020 moisturizing effect Effects 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 238000011012 sanitization Methods 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000000887 hydrating effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 21
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 210000002374 sebum Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 230000002225 anti-radical effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 229940064004 antiseptic throat preparations Drugs 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 150000001993 dienes Chemical class 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000037312 oily skin Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical class C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- NBVZMBLJRHUOJR-UHFFFAOYSA-N [amino-[4-[6-[4-[amino(azaniumylidene)methyl]phenoxy]hexoxy]phenyl]methylidene]azanium;2-hydroxyethanesulfonate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 NBVZMBLJRHUOJR-UHFFFAOYSA-N 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960001715 hexamidine isethionate Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229940099367 lanolin alcohols Drugs 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940072254 proscar Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100459 steareth-20 Drugs 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Abstract
Description
COMPOSITION COSMETIQUE OU DERMATOLOGIQUE BASECOSMETIC OR DERMATOLOGICAL COMPOSITION BASE
D'HUILES ESSENTIELLES UTILE POUR LE SOIN DE LA PEAU, PLUS ESSENTIAL OILS USEFUL FOR SKIN CARE, MORE
PARTICULI REMENT CHEZ L'HOMMEPARTICULARLY IN MAN
La présente invention a pour objet de nouvelles compositions cosmétiques et/ou dermatologiques à base d'huiles essentielles de plantes et plus particulièrement de Romarin, de Cade et de Santal, remarquables pour leurs effets bénéfiques sur la peau. Ces compositions sont 10 particulièrement utiles pour régler les problèmes cutanés The present invention relates to new cosmetic and / or dermatological compositions based on essential oils of plants and more particularly rosemary, Cade and Sandal, remarkable for their beneficial effects on the skin. These compositions are particularly useful for resolving skin problems
chez les hommes.at men's.
La couche cornée normale d'un épiderme est un pavage de cellules dont la cohésion est assurée par le cément intercornéocytaire. La qualité de l'épiderme dépend 15 du maintien de la qualité de ce cément. En outre, le bon The normal horny layer of an epidermis is a cell tessellation whose cohesion is ensured by the intercornocytic cementum. The quality of the epidermis depends on the maintenance of the quality of this cementum. In addition, the good
équilibre du niveau d'hydratation de la peau permet de participer à cette cohésion. De même, la quantité de sébum, fonction de l'activité de l'enzyme 5 a réductase, doit être à un niveau optimum, or, chez les hommes, le niveau de 20 sébum est souvent trop important. balance of the level of hydration of the skin allows to participate in this cohesion. Likewise, the amount of sebum, a function of the activity of the enzyme reductase, must be at an optimum level, yet in men the level of sebum is often too great.
La peau grasse ou hyperséborrhéîque se caractérise par une peau luisante, parfois d'aspect huileux, épaisse, aux pores pilosébasés dilatés. L'hypersécrétion sébacée est le plus souvent liée à une hyperandrogénie due, soit à une 25 production d'androgène, soit à une hyperproduction au Oily or hyperseborrheal skin is characterized by shiny skin, sometimes oily in appearance, thick, with dilated pilosebaceous pores. Sebaceous hypersecretion is most often linked to hyperandrogenism due either to androgen production or to hyperproduction in the body.
niveau de la glande sébacée à partir des androgènes. level of the sebaceous gland from the androgens.
Une autre caractéristique de la peau grasse ou hyperséborrhéque est le renouvellement trop rapide des cellules de la couche cornée, ce qui entraîne une peau 30 épaissie dans la première jeunesse puis conduit à un effondrement des fibres de collagène et à l'apparition de Another characteristic of oily or hyperseborrhoeic skin is the too rapid renewal of the cells of the stratum corneum, resulting in thickened skin in the first youth then leading to a collagen collapse and the appearance of
rides précoces et profondes.early and deep wrinkles.
L'augmentation de la quantité de sébum entraîne une augmentation de la quantité des micro-organismes en général 35 et des pathogènes en particulier. Ces derniers se développent en anaérobie dans la phase grasse supplémentaire apportée par le sébum. Ainsi, une bactérie résidente anaérobie, Propioni bacterium acnes, prolifère dans cet environnement riche en sébum et en cellules folliculaires. Cette prolifération microbienne a souvent pour conséquence une irritation des tissus cutanés, qui est en grande partie due à la libération des acides gras par les lipases bactériennes. Il est donc important de proposer une 10 composition permettant à la fois d'hydrater l'épiderme, de maintenir la cohésion cellulaire, de réguler le taux de Increasing the amount of sebum results in an increase in the amount of microorganisms in general and pathogens in particular. These grow anaerobically in the extra fatty phase provided by the sebum. Thus, an anaerobic resident bacterium, Propioni bacterium acnes, proliferates in this environment rich in sebum and follicular cells. This microbial proliferation often results in skin tissue irritation, which is largely due to the release of fatty acids by bacterial lipases. It is therefore important to propose a composition that makes it possible both to moisturize the epidermis, to maintain cellular cohesion, to regulate the rate of
sébum et de réduire l'irritation des tissus. sebum and reduce tissue irritation.
Il est proposé dans l'art antérieur de nombreuses compositions cosmétiques et/ou dermatologiques destinées à 15 traiter les peaux masculines. Elles contiennent généralement: - des actifs humectants, tels que les polyols et des facteurs du NMF cutané tels que l'urée, l'acide pyrrolidone carboxylique, les acides aminés, les sucres; - des agents kératolytiques comme les acides alpha hydroxylés, l'urée, l'acide salicylique; - des antiseptiques comme le triclosan, le phenoxyéthanol, l'hexamidine iséthionate, les dérivés de ketoconazole, l'octopirox, l'acide undécylénique et ses 25 sels, le peroxyde de benzoyle, l'acide azélaque; - des filmogènes hydrophobes, qui freinent la déperdition transcutanée d'eau, sont aussi couramment It is proposed in the prior art many cosmetic and / or dermatological compositions for treating male skin. They generally contain: humectant active agents, such as polyols and cutaneous NMF factors such as urea, pyrrolidone carboxylic acid, amino acids, sugars; keratolytic agents such as hydroxylated alpha acids, urea, salicylic acid; antiseptics such as triclosan, phenoxyethanol, hexamidine isethionate, ketoconazole derivatives, octopirox, undecylenic acid and its salts, benzoyl peroxide, azelaic acid; Hydrophobic film-formers, which slow down the transcutaneous loss of water, are also common
utilisés dans ces compositions.used in these compositions.
Toutes ces compositions apportent un traitement de 30 surface partiel qui contribue au maintien de l'équilibre de l'épiderme, mais elles présentent des effets limités dans le temps. En outre, la plupart des ingrédients cidessus sont issus de l'industrie chimique, et aucun produit n'est élaboré uniquement à partir d'huiles essentielles 35 naturelles. Il subsiste donc le besoin de produits qui apportent un traitement plus complet en profondeur permettant d'assainir la peau et de réguler la quantité des micro-organismes en général et des pathogènes en particulier. A la suite d'importantes recherches menées dans le domaine des produits permettant la correction spécifique des problèmes masculins, la Demanderesse a mis en évidence qu'une association d'huiles essentielles (HE) particulières permet de corriger, voire de régler, les problèmes de peaux 10 chez l'homme évoqués ci-dessus. Ce but est atteint selon All of these compositions provide a partial surface treatment which contributes to the maintenance of epidermal equilibrium, but they have limited effects over time. In addition, most of the above ingredients are from the chemical industry, and no products are made solely from natural essential oils. There is therefore still a need for products that provide a more thorough treatment in depth to cleanse the skin and regulate the amount of microorganisms in general and pathogens in particular. Following extensive research conducted in the field of products for the specific correction of male problems, the Applicant has shown that a combination of essential oils (HE) particular can correct or even solve the problems of skins 10 in humans mentioned above. This goal is achieved according to
l'invention grâce à une composition cosmétique ou dermatologique comprenant une huile essentielle (HE) de cade et au moins une autre huile essentielle choisie dans le groupe comprenant les huiles essentielles de Romarin, de 15 Santal et d'Hélichryse. the invention by means of a cosmetic or dermatological composition comprising a cade essential oil (HE) and at least one other essential oil chosen from the group comprising the essential oils of rosemary, sandalwood and helichrysum.
Une composition préférée selon l'invention comprend A preferred composition according to the invention comprises
des huiles essentielles de cade, de Romarin et de Santal. essential oils of cade, rosemary and sandalwood.
Cette composition préférée peut aussi contenir une huile This preferred composition may also contain an oil
essentielle d'Hélichryse.essential of Helichrysum.
La combinaison d'huiles essentielles des compositions de l'invention permettent d'obtenir, par un effet de synergie, des compositions cosmétiques ou dermatologiques ayant d'excellentes propriétés hydratantes, The combination of essential oils of the compositions of the invention make it possible to obtain, by a synergistic effect, cosmetic or dermatological compositions having excellent moisturizing properties,
séborrégulatrices, antiseptiques et apaisantes. seborrégulatrices, antiseptics and soothing.
En outre, ces compositions sont remarquables en ce qu'elles permettent d'obtenir les effets ci-dessus de façon durable. Ainsi, l'utilisation des compositions selon l'invention permet d'opérer un traitement en profondeur qui 30 assainit et restaure la barrière lipidique de l'épiderme, favorise une activité hydratante prolongée dans le temps, corrige les problèmes des peaux grasses et limite la prolifération des micro-organismes à la surface de l'épiderme. L'huile essentielle de Cade est présente entre 0,006 % et 6 %, de préférence entre 0,06 % et 3 % et tout préférentiellement entre 0,01 % et 1 % en poids de la In addition, these compositions are remarkable in that they make it possible to obtain the above effects in a sustainable manner. Thus, the use of the compositions according to the invention makes it possible to perform a deep treatment which cleanses and restores the lipid barrier of the epidermis, promotes hydration activity which is prolonged over time, corrects the problems of oily skin and limits the proliferation of microorganisms on the surface of the epidermis. The essential oil of Cade is present between 0.006% and 6%, preferably between 0.06% and 3% and most preferably between 0.01% and 1% by weight of the
composition de l'invention.composition of the invention.
L'huile essentielle de Romarin est présente entre 0,0001 % et 5 %, de préférence entre 0,005 % et 0,75 % et tout préférentiellement encore entre 0,01 % et 0,15 %. en The essential oil of rosemary is present between 0.0001% and 5%, preferably between 0.005% and 0.75% and still more preferably between 0.01% and 0.15%. in
poids de la composition.weight of the composition.
L'huile essentielle de Santal est présente entre 10 0,0001 % et 5 %, de préférence entre 0,005 % et 0,75 % et tout préférentiellement entre 0,01 % et 0,15 % en poids de The essential oil of Sandalwood is present between 0.0001% and 5%, preferably between 0.005% and 0.75% and most preferably between 0.01% and 0.15% by weight of
la composition.the composition.
L'huile essentielle d'Hélichryse, peut être présente entre 0,0001 % et 10 %, de préférence entre 0,001 15 % et 0,5 % et tout préférentiellement entre 0,01 % et 0,1 % The essential oil of Helichrysum can be present between 0.0001% and 10%, preferably between 0.001% and 0.5% and most preferably between 0.01% and 0.1%.
en poids de la composition de l'invention. by weight of the composition of the invention.
Selon une forme préférée de réalisation de la composition de l'invention, sa teneur totale en huiles 20 essentielles représente entre 0,005 % et 30 % et de According to a preferred embodiment of the composition of the invention, its total essential oil content is between 0.005% and 30% and
préférence entre 0,01% et 10 % en poids de la composition. preferably between 0.01% and 10% by weight of the composition.
L'huile essentielle de cade peut être obtenue par hydrodistillation ou à l'aide d'un fluide d'extraction de 25 préférence à l'état supercritique ou proche. Le même mode d'extraction concerne les autres huiles essentielles du groupe comprenant les huiles essentielles de Romarin, Santal ou Hélichryse. L'extraction de l'huile essentielle pour ce type de végétal s'effectue classiquement à l'aide 30 d'un générateur de vapeur d'o le fluide vaporisé est The essential oil of cade can be obtained by hydrodistillation or with the aid of an extraction fluid preferably in the supercritical or near state. The same method of extraction concerns the other essential oils of the group comprising the essential oils of rosemary, sandalwood or helichrysum. The extraction of the essential oil for this type of plant is conventionally carried out using a steam generator where the vaporized fluid is
conduit par une tubulure dans le fond d'une chambre d'extraction dans laquelle sont enfermés les végétaux. led by a tubing in the bottom of an extraction chamber in which the plants are enclosed.
Cette installation est reliée à un dispositif de maintien de pression régulée. Les fluides d'extraction sont conduits 35 dans un serpentin de refroidissement. La séparation finale des fluides d'extraction et des composants des huiles essentielles s'effectue à la pression atmosphérique par différence de densité. Cette technique a été souvent This installation is connected to a regulated pressure maintenance device. The extraction fluids are conducted in a cooling coil. The final separation of the extraction fluids and the components of the essential oils is carried out at atmospheric pressure by difference in density. This technique has often been
décrite dans la littérature spécialisée. described in the specialized literature.
Les compositions selon l'invention peuvent également comprendre d'autres actifs généralement utilisés en cosmétique ou dermatologie, comme par exemple des agents hydratants, restructurants, séborrégulateurs, anti10 inflammatoires et antiseptiques de la peau. Ces actifs, s'ils sont présents, peuvent représenter de 1 à 20 % de The compositions according to the invention may also comprise other active agents generally used in cosmetics or dermatology, for example moisturizing, restructuring, seborrégulateurs, anti-inflammatories and antiseptics of the skin. These assets, if present, can represent from 1 to 20% of
préférence de 1 à 10 % en poids de la composition. preferably from 1 to 10% by weight of the composition.
Les compositions selon l'invention peuvent se 15 présenter sous toutes les formes galéniques classiquement utilisées, et bien connues de l'homme de l'art, dans les domaines cosmétiques ou dermatologiques pour être appliquées sur la peau, comme par exemple, des émulsions Huile dans Eau (H/E) ou Eau dans Huile (E/H), des lotions, 20 shampooings, sprays, gels ou gels moussants pour la douche, des laits, des masques, des crèmes, etc. sans aucune restriction galénique particulière autre que celles de la compatibilité avec les huiles essentielles à la base de la composition. Ainsi, les compositions de l'invention peuvent 25 aussi contenir tous les constituants classiquement utilisés dans ces présentations comme des agents de formulation, des agents tensio-actifs, des agents conservateurs, des agents solubilisants, des agents gélifiants, des additifs gras non végétaux, du propylène glycol, du sorbitol, du glycérol, de 30 la triéthanolamine, des bases de parfums, de l'eau en The compositions according to the invention may be in any of the galenical forms conventionally used, and well known to those skilled in the art, in the cosmetic or dermatological fields to be applied to the skin, for example, oil emulsions. in Water (O / W) or Water in Oil (W / O), lotions, shampoos, sprays, shower gels or gels, milks, masks, creams, etc. without any particular pharmaceutical restriction other than those of the compatibility with the essential oils at the base of the composition. Thus, the compositions of the invention may also contain all the constituents conventionally used in these presentations as formulating agents, surfactants, preserving agents, solubilizing agents, gelling agents, non-vegetable fatty additives, propylene glycol, sorbitol, glycerol, triethanolamine, perfume bases, water in
quantité suffisante pour 100.sufficient amount for 100.
Ainsi, l'invention a aussi pour objet une méthode de soin cosmétique consistant à appliquer sur la peau une Thus, the subject of the invention is also a method of cosmetic care consisting in applying to the skin a
quantité adéquate d'une composition définie précédemment. adequate amount of a previously defined composition.
Comme déjà indiqué, les compositions selon l'invention sont utiles pour le soin de la peau, en particulier celle des hommes. Elles permettent un soin durable et en profondeur de la peau notamment en 5 assainissant et restaurant la barrière lipidique de l'épiderme, en favorisant une activité hydratante prolongée dans le temps, en corrigeant les problèmes des peaux grasses, en réduisant le taux de sébum et en limitant la prolifération des micro-organismes à la surface de 10 l'épiderme. L'invention concerne donc aussi l'utilisation d'huile essentielle de cade pour la préparation d'une composition cosmétique ou dermatologique utile pour le soin et le traitement de la peau, ladite huile étant associée dans ladite composition avec au moins une autre huile 15 essentielle choisie dans le groupe comprenant les huiles essentielles de Romarin, de Santal et d'Hélichryse. Ces As already indicated, the compositions according to the invention are useful for the care of the skin, in particular that of men. They allow a long-lasting and deep skin care including sanitizing and restoring the lipid barrier of the epidermis, promoting a moisturizing activity extended over time, correcting the problems of oily skin, reducing sebum and by limiting the proliferation of microorganisms on the surface of the epidermis. The invention therefore also relates to the use of essential oil of cade for the preparation of a cosmetic or dermatological composition useful for the care and treatment of the skin, said oil being associated in said composition with at least one other oil. essential oil selected from the group consisting of Rosemary, Sandalwood and Helichrysum essential oils. These
compositions sont celles décrites précédemment. compositions are those described above.
Tout particulièrement, l'invention s'intéresse à l'utilisation cosmétique d'une association d'huiles 20 essentielles comme définie précédemment pour apaiser, assainir, hydrater et restructurer la peau plus In particular, the invention is concerned with the cosmetic use of a combination of essential oils as defined above for soothing, sanitizing, moisturizing and restructuring the skin.
particulièrement chez les hommes.especially in men.
D'autres caractéristiques et avantages de la Other features and benefits of the
présente invention apparaîtront à la lecture des exemples 25 non limitatifs qui suivent. The present invention will become apparent on reading the nonlimiting examples which follow.
Exemple 1: Crème Hydratante.Example 1: Moisturizing Cream.
Stéarate de sucrose 0,5 à 6 % Distéarate de sucrose 0,5 à 6 % Triglycéride caprylique/caprique 3 à 15 % Triglycéride caprylique/caprique/succinique 3 à 15 % HE de Cade 0,10 à 0,30 % HE de Romarin 0,05 à 0,07 % HE de Hélichryse 0,03 à 0,06 % HE de Santal 0,05 à 0,07 % Acétate de tocophéryle Urée Glycérine Acide citrique Citrate trisodique Hyaluronate de sodium Sorbate de potassium Gomme sclerotium Gomme xanthane 10 Eau Parfum Conservateurs Sucrose Stearate 0.5 to 6% Sucrose Distearate 0.5 to 6% Caprylic / Capric Triglyceride 3 to 15% Caprylic / Capric / Succinic Triglyceride 3 to 15% HE Cade 0.10 to 0.30% HE Rosemary 0.05 to 0.07% HE Helichrysum 0.03 to 0.06% HE Sandalwood 0.05 to 0.07% Tocopheryl acetate Urea Glycerin Citric acid Trisodium citrate Sodium hyaluronate Potassium sorbate Sclerotium gum Xanthan gum 10 Eau Parfum Conservatives
0,05 à 1 % 0,5 à 2 % 0,5 à 3 % 0,1 à 0,5 % 0,5 à 1,5 % 0,5 à 3 % 0,2 à 0, 5 % 0,1 à 0,5 % 0,1 à 0,5 % qsp.100 % qs. 0.05 to 1% 0.5 to 2% 0.5 to 3% 0.1 to 0.5% 0.5 to 1.5% 0.5 to 3% 0.2 to 0.5% 0, 1 to 0.5% 0.1 to 0.5% qsp.100% qs.
qs.qs.
Exemple 2: Crème régénérante, seborrégulatrice. Example 2: Regenerating cream, seborrégégatrice.
Céramide 3 0,1% Palmitate de vitamine A 0,15 % Stéareth-20 0,2 % Methyl paraben 0,25 % Eau qsp. 100 % HE de Cade 0,25 % HE de Romarin 0,10 % HE de Santal 0,10 % Stéareth-2 1 à 3 % Alcool cétyl stéarylique 2 à 4% Myristate de myristyle 2 à 4% Myristate d'isopropyle 4% Glycérine 1% Dimethicone 0,5 % Alcools lanoliniques 0,5 % Propyl paraben 0,25 % Ceramide 3 0.1% Palmitate vitamin A 0.15% Steareth-20 0.2% Methyl paraben 0.25% Water qsp. 100% HE Cade 0.25% HE Rosemary 0.10% HE Sandalwood 0.10% Steareth-2 1 to 3% Cetyl Stearyl Alcohol 2 to 4% Myristyl Myristate 2 to 4% Isopropyl Myristate 4% Glycerin 1% Dimethicone 0.5% Lanolin Alcohols 0.5% Propyl Paraben 0.25%
Exemple 3: Crème anti-radicalaire.Example 3 Anti-radical cream.
Oléate de sorbitane Polysorbate 80 Huile de germe de blé 3,5 % Sorbitan oleate Polysorbate 80 Wheat germ oil 3.5%
2 à 4 %2-4%
3 % Huile d'amande douce Myristate d'isopropyle Polyacrylamide & C14-13 isoparaffine & laureth-7 Palmitate de vitamine A Tocophérol PCANa Hyaluronate de sodium Eau Conservateurs HE de Cade HE de Romarin HE de Hélichryse HE de Santal % 12 % 2 à 3,5 % 0,1 % 0,05 % 0,5 % 0,1 % qsp 100 % qsp 0,20 % 0,03 % 0,01 % 0,02 % 3% Sweet Almond Oil Isopropyl Myristate Polyacrylamide & C14-13 Isoparaffin & Laureth-7 Palmitate Vitamin A Tocopherol PCANa Sodium Hyaluronate Water Preservatives HE Cade HE Rosemary HE Helichrysum HE Sandalwood% 12% 2 to 3 , 5% 0.1% 0.05% 0.5% 0.1% qs 100% qs 0.20% 0.03% 0.01% 0.02%
Exemple 4: Shampooing.Example 4: Shampoo.
Sodium lauroyl oat aminoacids 5,00 % Sodium coceth sulfate/PEG-40 glyceryl cocoate17,00 % Alcool benzylique 0,20 % Dimethicone copolyol 2, 00 % Eau qsp 100 % HE de Cade 0,05 % HE de Romarin 0,02 % HE de Hélichryse 0,01% HE de Santal 0,02 % Acrylates copolymere 3 % Conservateurs qsp NaOH qsp pH = 7,2 Sodium lauroyl oat aminoacids 5.00% Sodium coceth sulfate / PEG-40 glyceryl cocoate17.00% Benzyl alcohol 0.20% Dimethicone copolyol 2.00% Water qs 100% Cade HE 0.05% HE Rosemary 0.02% Helichrysum HE 0.01% HE Sandalwood 0.02% Acrylates copolymer 3% Preservatives qsp NaOH qsp pH = 7.2
Exemple 5: Huile de bain aux huiles essentielles. Example 5: Bath oil with essential oils.
Huile essentielle de Lavande 18,00 % HE de Cade 0,10 % HE de Romarin 0,05 % HE de Hélichryse 0,02 % HE de Santal 0,05 % Decyl glucoside 36,00 % Glycérine 43,00 % Conservateur 0,50 % Extrait de plancton 0,10 % Exemple 6 Propriété des compositions selon l'invention. Les tests ci-après ont été réalisés avec des 10 compositions types selon l'invention comprenant un complexe Lavender essential oil 18.00% HE Cade 0.10% HE Rosemary 0.05% HE Helichrysum 0.02% HE Sandalwood 0.05% Decyl glucoside 36.00% Glycerin 43.00% Preservative 0, 50% plankton extract 0.10% Example 6 Property of the compositions according to the invention. The following tests were carried out with standard compositions according to the invention comprising a complex
d'huiles essentielles constitué par de l'ordre de 50 à 60 % d'huile essentielle de cade et de 30 à 40 % d'au moins une des huiles essentielles de romarin, de santal et d'hélichyse, à plusieurs dilutions (0,01 %, 0,10 %, 0,20 % 15 et 1,00 %). of essential oils consisting of about 50 to 60% of essential oil of cade and 30 to 40% of at least one of the essential oils of rosemary, sandalwood and helichysis, in several dilutions (0 , 0.1%, 0.10%, 0.20% and 1.00%).
1) Pouvoir anti-radicalaire du complexe d'huiles essentielles. Le radical hydroxyle est une molécule très réactive dont la production est activée par les différents 20 stress subits par la peau (pollution, V, variations de 1) Anti-radical power of the complex of essential oils. The hydroxyl radical is a very reactive molecule, the production of which is activated by the various stresses undergone by the skin (pollution, V, variations in
température, etc). Il est responsable de nombreux dégâts dans la cellule et notamment de la dégradation des membranes par le phénomène de peroxydation lipidique. temperature, etc.). It is responsible for numerous cell damage including membrane degradation by lipid peroxidation.
L'objectif de la présente étude a été d'apprécier le 25 pouvoir antiradicalaire de la composition d'huiles essentielles selon la présente invention par la méthode in vitro des diènes conjugués. Cette méthode permet de tester l'action protectrice du produit sur des liposomes (analogues de membrane) soumis à une attaque de radicaux 30 hydroxyles (OH-) L'action des radicaux libres sur les acides gras polyinsaturés des membranes est une peroxydation qui conduit à la formation de diènes conjugués absorbants à 233 nm. L'activité des antioxydants est donc dosée par leur 35 capacité à empêcher la peroxydation d'acides graspolyinsaturés contenus dans des liposomes (modèle in vitro se rapprochant le plus de la réalité in vivo). Cette peroxydation est caractérisée par un pic d'absorption à 233 nm. La méthode et le protocole utilisés sont par exemple décrits dans la littérature. Au terme de l'essai, il apparaît que la composition d'huiles essentielles selon la présente invention inhibe la peroxydation lipidique de 85 % en moyenne par rapport à un témoin non protégé. Cet excellent résultat est prédictif 10 d'un effet anti-inflammatoire particulièrement adapté au traitement des peaux masculines à tendance grasse. Cette activité anti-radicalaire est essentielle dans la lutte contre le vieillissement accéléré provoqué par le turn-over The objective of the present study was to assess the antiradical potency of the essential oil composition according to the present invention by the in vitro method of conjugated dienes. This method makes it possible to test the protective action of the product on liposomes (membrane analogues) subjected to attack by hydroxyl radicals (OH-). The action of free radicals on the polyunsaturated fatty acids of the membranes is a peroxidation which leads to the formation of absorbent conjugated dienes at 233 nm. Antioxidant activity is therefore assayed by their ability to prevent peroxidation of liposome-containing graspolyunsaturated acids (in vitro model closest to in vivo reality). This peroxidation is characterized by an absorption peak at 233 nm. The method and the protocol used are for example described in the literature. At the end of the test, it appears that the composition of essential oils according to the present invention inhibits the lipid peroxidation of 85% on average compared to an unprotected control. This excellent result is predictive of an anti-inflammatory effect particularly suitable for the treatment of oily-looking male skins. This anti-radical activity is essential in the fight against accelerated aging caused by turnover
trop important des peaux à tendance grasse ou séborréique. 15 2) Inhibition de la 5 a. réductase. Too important skins fat or seborrheic. 2) Inhibition of the 5 a. reductase.
En outre, il a été aussi constaté que la composition d'huiles essentielles selon l'invention présente un effet inhibiteur vis-à-vis de la 5 ax réductase. La 5 a réductase est une enzyme qui catalyse 20 l'hydroxylation de la testostérone en 5dihydrotestostérone, métabolite présentant une activité androgénique importante et régulant le métabolisme de la In addition, it has also been found that the composition of essential oils according to the invention has an inhibitory effect vis-à-vis the 5 ax reductase. 5α-Reductase is an enzyme that catalyzes the hydroxylation of testosterone to the dihydrotestosterone, a metabolite exhibiting significant androgenic activity and regulating the metabolism of the testosterone.
glande sébacée.sebaceous gland.
Le but était de vérifier que la composition 25 d'huiles essentielles selon l'invention permet aussi de The purpose was to verify that the composition of essential oils according to the invention also makes it possible to
bénéficier d'un effet inhibiteur vis-à-vis de la bio transformation de la testostérone. Le test a été mené sur des fibroblastes humains et le produit de référence est le finastéride, principe actif connu des comprimés CHIBRO30 PROSCAR des laboratoires MERCK SHAR & DOHME CHIBRET. benefit from an inhibitory effect vis-à-vis the bio transformation of testosterone. The test was conducted on human fibroblasts and the reference product is finasteride, active ingredient known tablets CHIBRO30 PROSCAR laboratories MERCK SHAR & DOHME CHIBRET.
La testostérone utilisée est pour une part marquée. The testosterone used is partly marked.
Les cellules ont été soumises à une pré-incubation dans les milieux de culture en présence du produit de référence ou de la composition d'huiles essentielles selon l'invention. 35 Après ajout du substrat, c'est-à-dire la testostérone, à la concentration de 1.10_6M dont 4.10-8M radiomarquées, les cellules sont incubées pendant une journée. Des cultures témoins sont réalisées en parallèle et les essais sont réalisés en triple exemplaire. Après incubation, les 5 cellules sont soniquées et une partie des homogénats est conservée pour le dosage des protéines cellulaires. Les homogénats sont extraits au dichlorométhane et après évaporation, les résidus secs sont repris au méthanol. Les dépôts sont effectués sur des plaques de silice, le solvant 10 de migration est un mélange de dichlorométhane/éther. Les plaques avec des éléments radiomarqués sont lues avec un analyseur de radioactivité et les éléments standards sont traités à l'acide sulfurique dilué et chauffé à 1000 C. Le dosage des protéines cellulaires est réalisé par la méthode 15 de BRADFORD. Les résultats sont exprimés en ng de protéine par puits de culture. Les résultats obtenus montrent une amélioration de 57 % par rapport au témoin non traité par The cells were preincubated in the culture media in the presence of the reference product or the essential oil composition according to the invention. After addition of the substrate, ie testosterone, at the concentration of 1.10 6M including 4.10-8M radiolabeled, the cells are incubated for one day. Control cultures are carried out in parallel and the tests are carried out in triplicate. After incubation, the cells are sonicated and some of the homogenates are stored for the determination of cellular proteins. The homogenates are extracted with dichloromethane and after evaporation, the dry residues are taken up in methanol. The deposits are carried out on silica plates, the migration solvent is a mixture of dichloromethane / ether. The plates with radiolabeled elements are read with a radioactivity analyzer and the standard elements are treated with dilute sulfuric acid and heated to 1000 C. The assay of the cellular proteins is carried out by the method of BRADFORD. The results are expressed in ng of protein per culture well. The results obtained show a 57% improvement over the untreated control by
les compositions selon l'invention.the compositions according to the invention.
La figure 1 en annexe rapporte les résultats de ce 20 test d'inhibition de la 5 alpha réductase et montre que les compositions selon l'invention ont bien une activité sur la 5 alpha réductase et sont donc utiles dans le traitement FIG. 1 in the appendix reports the results of this 5 alpha reductase inhibition test and shows that the compositions according to the invention do indeed have an activity on 5 alpha reductase and are therefore useful in the treatment.
des peaux grasses ou acnéiques.oily or acne-like skin.
3) Effet bactériostatique.3) Bacteriostatic effect.
La demanderesse a aussi déterminé le potentiel bactériostatique de la composition d'huiles essentielles de l'invention. Trois souches ont été utilisées dans la technique de l'aromatogramme Staphylococcus aureus, Pseudomonas fluorescens, Escherichia coli. Les souches sont 30 diluées dans de l'eau physiologique. Pour chaque souche, six boites de Pétri sont ensemencées avec 1 ml de solution fille. Pour obtenir une solution fille à partir de la solution mère, 0,1 ml est prélevé et placé dans 9,9 ml de bouillon caséine-soja. Une solution à 10-2 a ainsi été 35 obtenue. Pour obtenir une solution à 10-4, on utilise 0,1 ml de solution à 10-2 qui est introduite dans un bouillon de la même façon que précédemment. Il est possible d'obtenir ainsi de suite des solutions à 10-2, 10-4, 10-6, 10-8, 10-10. La solution mère est versée à raison d'un ml 5 dans chaque boite de Pétri. On coule la caséine-soja sur les boites. On dépose sur le milieu ensemencé des disques stériles imprégnés de 0,01 ml de la composition d'huiles essentielles. Chaque boite de Pétri est placée à l'étuve à 300 C. 10 Au bout de 24 heures, on procède à la lecture. Le diamètre d'inhibition est mesuré autour de chaque disque. L'effet bactéricide est noté de 0 à 4 en fonction de la zone d'inhibition. Comme le montre les résultats du tableau 2 ci15 dessous, l'effet bactériostatique des huiles essentielles est fortement augmenté dans un mélange synergique approprié. The Applicant has also determined the bacteriostatic potential of the composition of essential oils of the invention. Three strains were used in the aromatogram technique Staphylococcus aureus, Pseudomonas fluorescens, Escherichia coli. The strains are diluted in physiological saline. For each strain, six petri dishes are inoculated with 1 ml of daughter solution. To obtain a daughter solution from the stock solution, 0.1 ml is removed and placed in 9.9 ml of casein-soy broth. A 10-2 solution was thus obtained. To obtain a 10-4 solution, 0.1 ml of 10-2 solution is used which is introduced into a broth in the same manner as before. It is possible to obtain 10-2, 10-4, 10-6, 10-8, 10-10 solutions. The stock solution is poured at a rate of one ml into each petri dish. Casein-soy is poured on the boxes. Sterile discs impregnated with 0.01 ml of the essential oil composition are deposited on the seeded medium. Each petri dish is placed in an oven at 300 ° C. After 24 hours, the reading is carried out. The inhibition diameter is measured around each disk. The bactericidal effect is noted from 0 to 4 depending on the zone of inhibition. As shown by the results in Table 2 below, the bacteriostatic effect of the essential oils is greatly increased in a suitable synergistic mixture.
Tableau 1Table 1
Huile Staphylococcus Pseudomonas Echerichia essentielle aureus Fluoreces Coli Romarin... 0 ++ Cade + O + Santal.... + ++ Hélichryse + 0 0 Oil Staphylococcus Pseudomonas Echerichia essential aureus Fluoreces Coli Rosemary ... 0 ++ Cade + O + Sandal .... + ++ Helichrysum + 0 0
Composition ++++ ++...Composition ++++ ++ ...
de l'inventionof the invention
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0212543A FR2845594B1 (en) | 2002-10-09 | 2002-10-09 | COSMETIC OR DERMATOLOGICAL COMPOSITION BASED ON ESSENTIAL OILS USEFUL FOR SKIN CARE, PARTICULARLY IN MAN |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0212543A FR2845594B1 (en) | 2002-10-09 | 2002-10-09 | COSMETIC OR DERMATOLOGICAL COMPOSITION BASED ON ESSENTIAL OILS USEFUL FOR SKIN CARE, PARTICULARLY IN MAN |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2845594A1 true FR2845594A1 (en) | 2004-04-16 |
FR2845594B1 FR2845594B1 (en) | 2005-02-11 |
Family
ID=32039575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0212543A Expired - Lifetime FR2845594B1 (en) | 2002-10-09 | 2002-10-09 | COSMETIC OR DERMATOLOGICAL COMPOSITION BASED ON ESSENTIAL OILS USEFUL FOR SKIN CARE, PARTICULARLY IN MAN |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR2845594B1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006063056A1 (en) * | 2004-12-07 | 2006-06-15 | Access Business Group International Llc | Methods for scavenging oxidizing nitrogen and oxygen species with fragrances having antioxidative properties |
FR2886544A1 (en) * | 2005-06-01 | 2006-12-08 | Kiotis Soc Par Actions Simplif | Cosmetic use of essential oils to prevent and/or treat cutaneous dehydration and the damages causing a hydrous stress on the fibroblasts and to increase the viability of fibroblasts, in vitro culture, subjected to a hydrous stress |
US20110217395A1 (en) * | 2010-03-04 | 2011-09-08 | Komeh-Nkrumah Steva A | Therapeutic, Bio-Affecting And Body Treating Composition |
US8147878B2 (en) | 2006-01-17 | 2012-04-03 | Aboca S.P.A. Societa' Agricola | Water insoluble helychrisum extract, process for preparing the same and uses thereof |
US8986752B1 (en) * | 2013-12-05 | 2015-03-24 | Sherry May Raymond-Coblantz | Skin care treatment |
US8986755B1 (en) * | 2013-12-05 | 2015-03-24 | Sherry May Raymond-Coblantz | Skin moisturizer |
FR3019971A1 (en) * | 2014-04-22 | 2015-10-23 | Greenpharma Sas | REPULSIVE COMPOSITION FOR WILD ANIMALS OR DOMESTIC |
CN106109368A (en) * | 2016-03-31 | 2016-11-16 | 福建欧柏亚日化有限公司 | A kind of multiple-effect spy moistens care frost |
CN115463040A (en) * | 2022-09-27 | 2022-12-13 | 宝萃生物科技有限公司 | Water-emulsion double-layer quick-acting long-acting moisturizing skin care product and preparation method thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2216987A1 (en) * | 1973-02-08 | 1974-09-06 | Salles Pierre | |
US4009127A (en) * | 1974-06-21 | 1977-02-22 | Firmenich S.A. | Oxatricyclo compounds useful as perfuming agents |
FR2377195A1 (en) * | 1977-01-12 | 1978-08-11 | Thenoux Martine | Horse hoof care compsn. prodn. - by mixing animal fat, beeswax, cade oil, glutamate(s), vegetable tar and rosemary essence |
FR2587208A1 (en) * | 1985-09-19 | 1987-03-20 | Scherninski Francois | Lotion for combatting hair loss and promoting hair regeneration |
US4908349A (en) * | 1987-07-29 | 1990-03-13 | Givaudan Corporation | Bicyclic aldehydes and fragrance compositions containing same |
FR2674749A1 (en) * | 1991-04-05 | 1992-10-09 | Thorel Jean Noel | Cosmetic and dermatological bases based on essential oils, and corresponding processes and equipment |
DE4419470A1 (en) * | 1993-06-03 | 1994-12-08 | Petritsch Prod Gmbh | Process for the production of a skin and/or hair care composition from surfactants and water |
EP0737479A1 (en) * | 1991-09-05 | 1996-10-16 | Herta Mag. Haerpfer-Horn | Product for care of hide, skin and optionally hoof from animals, in particular from horses |
WO2000003762A1 (en) * | 1998-07-17 | 2000-01-27 | Bx3 General Labs S.A. | Method for cosmetic treatment of the skin and the scalp using electromagnetic waves and essential oils |
CN1247735A (en) * | 1999-09-09 | 2000-03-22 | 沈玉洁 | Face skin-care oil |
-
2002
- 2002-10-09 FR FR0212543A patent/FR2845594B1/en not_active Expired - Lifetime
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2216987A1 (en) * | 1973-02-08 | 1974-09-06 | Salles Pierre | |
US4009127A (en) * | 1974-06-21 | 1977-02-22 | Firmenich S.A. | Oxatricyclo compounds useful as perfuming agents |
FR2377195A1 (en) * | 1977-01-12 | 1978-08-11 | Thenoux Martine | Horse hoof care compsn. prodn. - by mixing animal fat, beeswax, cade oil, glutamate(s), vegetable tar and rosemary essence |
FR2587208A1 (en) * | 1985-09-19 | 1987-03-20 | Scherninski Francois | Lotion for combatting hair loss and promoting hair regeneration |
US4908349A (en) * | 1987-07-29 | 1990-03-13 | Givaudan Corporation | Bicyclic aldehydes and fragrance compositions containing same |
FR2674749A1 (en) * | 1991-04-05 | 1992-10-09 | Thorel Jean Noel | Cosmetic and dermatological bases based on essential oils, and corresponding processes and equipment |
EP0737479A1 (en) * | 1991-09-05 | 1996-10-16 | Herta Mag. Haerpfer-Horn | Product for care of hide, skin and optionally hoof from animals, in particular from horses |
DE4419470A1 (en) * | 1993-06-03 | 1994-12-08 | Petritsch Prod Gmbh | Process for the production of a skin and/or hair care composition from surfactants and water |
WO2000003762A1 (en) * | 1998-07-17 | 2000-01-27 | Bx3 General Labs S.A. | Method for cosmetic treatment of the skin and the scalp using electromagnetic waves and essential oils |
CN1247735A (en) * | 1999-09-09 | 2000-03-22 | 沈玉洁 | Face skin-care oil |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 200042, Derwent World Patents Index; AN 2000-476870, XP002242043 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006063056A1 (en) * | 2004-12-07 | 2006-06-15 | Access Business Group International Llc | Methods for scavenging oxidizing nitrogen and oxygen species with fragrances having antioxidative properties |
FR2886544A1 (en) * | 2005-06-01 | 2006-12-08 | Kiotis Soc Par Actions Simplif | Cosmetic use of essential oils to prevent and/or treat cutaneous dehydration and the damages causing a hydrous stress on the fibroblasts and to increase the viability of fibroblasts, in vitro culture, subjected to a hydrous stress |
US8147878B2 (en) | 2006-01-17 | 2012-04-03 | Aboca S.P.A. Societa' Agricola | Water insoluble helychrisum extract, process for preparing the same and uses thereof |
US20110217395A1 (en) * | 2010-03-04 | 2011-09-08 | Komeh-Nkrumah Steva A | Therapeutic, Bio-Affecting And Body Treating Composition |
US8821948B2 (en) * | 2010-03-04 | 2014-09-02 | Steva A. Komeh-Nkrumah | Therapeutic, bio-affecting and body treating composition |
US8986752B1 (en) * | 2013-12-05 | 2015-03-24 | Sherry May Raymond-Coblantz | Skin care treatment |
US8986755B1 (en) * | 2013-12-05 | 2015-03-24 | Sherry May Raymond-Coblantz | Skin moisturizer |
FR3019971A1 (en) * | 2014-04-22 | 2015-10-23 | Greenpharma Sas | REPULSIVE COMPOSITION FOR WILD ANIMALS OR DOMESTIC |
CN106109368A (en) * | 2016-03-31 | 2016-11-16 | 福建欧柏亚日化有限公司 | A kind of multiple-effect spy moistens care frost |
CN115463040A (en) * | 2022-09-27 | 2022-12-13 | 宝萃生物科技有限公司 | Water-emulsion double-layer quick-acting long-acting moisturizing skin care product and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
FR2845594B1 (en) | 2005-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2174598C (en) | Use of an inhibitor of an hmg-coenzyme-a reductase to prevent aging of the skin or to stimulate the process of epidermal renewal | |
EP2332520B1 (en) | Lactobacillus paracasei for treating age spots and / or melasma | |
CN110831571A (en) | Cosmetic composition for skin health and method of use thereof | |
FR2921255A1 (en) | Cosmetic use of jasmonic acid derivative, to prepare a composition for depigmenting and bleaching of the skin, to reduce or eliminate the pigmentation, and/or to reduce the size of lentigo | |
FR2950884A1 (en) | USE OF VANILLIN DERIVATIVES AS A PRESERVATIVE, METHOD OF PRESERVATION, COMPOUNDS AND COMPOSITION | |
EP2305212A1 (en) | Composition comprising one extract of at least one filamentous bacterium and process for treating signs of ageing thereof | |
FR3004939A1 (en) | SATUREJA MONTANA ESSENTIAL OIL WITH HIGH GERANIOL CONTENT AND USE FOR TREATING FAT SKINS AND / OR ASSOCIATED AESTHETIC DEFECTS | |
EP0953345B1 (en) | Use of at least a hydroxystilbene as an agent for decreasing micro-organisms adhesion | |
EP0756866B1 (en) | Use of benzoic acid derivatives for stimulating the renewal of the epidermis and for treating the skin | |
EP1401383A2 (en) | Use of at least an oil extracted from the seeds of the gourd family for preparing a composition for inhibiting 5-alpha-reductase activity | |
FR2845594A1 (en) | Cosmetic or dermatological composition useful for care and treatment of the skin comprises Spanish juniper oil and rosemary, sandalwood and/or helichrysum oil | |
EP2694027B1 (en) | Use of (ethoxy-hydroxy phenyl)alkyl ketone or ethoxy hydroxy alkyl phenol compounds for treating oily skin | |
EP1375509A1 (en) | Use of a sapogenin, or a natural extract containing the same, for the treatment of oligoseborrheic dry skin | |
WO2008044636A1 (en) | Anti-wrinkle agent and skin preparation for external use | |
EP1272156A1 (en) | Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials | |
FR2981275A1 (en) | MEROTERPENE-BASED COMPOSITION FOR OILY SKIN, ACNETIC SKIN OR ACNE-DENIED | |
WO2013098519A2 (en) | Use of a composition for preventing and combating the effects of tobacco on the skin | |
FR2994527A1 (en) | Use of essential oil of Laserpitium siler L. as active agent to prevent and/or treat skin imperfections such as irregular relief, dilated pores, comedones and/or blackheads associated with development of Propionibacterium acnes germs | |
FR2859102A1 (en) | USE OF A RHODIOLA CRENULATA EXTRACT BY TOPIC | |
EP1366743A1 (en) | Use of a derivative of 7-oxydated DHEA for treating dry skin | |
KR20000018910A (en) | Composition for acne skin | |
FR2960436A1 (en) | Use of an essential oil of cedar in an anti-aging cosmetic composition, which is useful for strengthening the barrier function, for the cohesion of skin cells, for the regulation of hydration of the skin, and for improving skin tone | |
EP1155685B1 (en) | Composition containing manganese | |
JP2005281279A (en) | Lipase inhibitor and external preparation for improving pimple | |
FR3004937A1 (en) | USE OF AN ESSENTIAL OIL OF ORIGANUM MAJORANA AS AGENT FOR TREATING AND / OR PREVENTING FAT SKINS AND / OR ASSOCIATED SKIN AHEET DEFECTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CD | Change of name or company name |
Owner name: LABORATOIRES M&L, FR Effective date: 20120413 |
|
PLFP | Fee payment |
Year of fee payment: 15 |
|
PLFP | Fee payment |
Year of fee payment: 16 |
|
PLFP | Fee payment |
Year of fee payment: 17 |
|
PLFP | Fee payment |
Year of fee payment: 18 |
|
PLFP | Fee payment |
Year of fee payment: 19 |
|
PLFP | Fee payment |
Year of fee payment: 20 |